Anaptysbio, Inc (ANAB): Cash & Equivalents
$238.20M
As of 2025-12-31
$248.47M
As of 2026-03-31
+49.5%
3-year compound annual growth
-1.0%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $238.20M | +93.5% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $123.08M | +242.2% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $35.97M | -49.6% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $71.31M | -85.6% | 2024-03-11, Balance as of period end |
| 2021-12-31 | $495.73M | +97.9% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $250.46M | +46.5% | 2022-03-07, Balance as of period end |
| 2019-12-31 | $171.02M | +50.5% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $113.60M | +39.9% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $81.19M | +58.5% | 2019-02-28, Balance as of period end |
| 2016-12-31 | $51.23M | n/a | 2018-03-05, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $238.20M | +93.5% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $184.84M | +256.4% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $29.64M | -57.2% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $287.42M | -48.7% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $222.00M | +48.0% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $112.83M | +33.7% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $84.85M | -17.1% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $230.52M | +56.5% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $134.66M | +11.3% |
Compare ANAB, AKBA, PBYI, KROS side by side · Screen every company in Pharmaceutical Preparations ↗